Navigation Links
ViroPharma to Participate in the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
Date:2/11/2011

EXTON, Pa., Feb. 11, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Leerink Swann Hot Topics in Therapeutics Roundtable Conference at 2:40 P.M. ET on Thursday, February 17, 2011.  The conference is being held at the Roosevelt Hotel in New York City.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze® (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx).  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media s
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Participate in the 29th Annual J.P. Morgan Healthcare Conference
2. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
3. ViroPharma to Release 2010 Second Quarter Financial Results on July 28, 2010
4. ViroPharma Introduces New Reconstitution System for Cinryze™ (C1 Esterase Inhibitor [Human])
5. ViroPharma Announces Availability of Cinryze(TM) (C1 Esterase Inhibitor [Human]) Final Open-Label Data
6. ViroPharma to Participate in Two May Healthcare Investor Conferences
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma to Present at Four Additional Healthcare Conferences
9. ViroPharma to Present at Several Upcoming Healthcare Conferences
10. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 26, 2014 The ... from a survey of European physicians at the ... Innovation and Biological Therapies" at the Spanish Ministry ... hosted by EuropaBio and the Spanish Bioindustry Association ... Health, physicians from Spanish oncology and rheumatology societies, ...
(Date:11/26/2014)... November 25, 2014 SonaCare Medical, ... Ultrasound (HIFU) devices, recently participated in the American ... Mass 360° .” Key opinion leaders in urology ... related to small renal masses while attendees had ... ablative technologies in hands-on labs. Attendees at the ...
(Date:11/26/2014)... Miles Holder, formerly of Micron Research ... Products team as Sales/Marketing Manager. Mr. Holder has over ... for the graphite industry. , “We are thrilled to ... Dave Trinkley, VP of Market and Product Development for ... in the graphite industry, along with his proven track ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
Breaking Biology Technology:ASBM Presents European Physicians Survey at Spanish Ministry of Health 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3Miles Holder Joins Graphel Corporation as Sales/Marketing Manager 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... Calif., Dec. 5, 2011 OvaGene Oncology Inc., ... and commercialization of personalized gene-based diagnostics for gynecologic ... major Licensing and Collaboration Agreement with The Moffitt ... Comprehensive Cancer Center in Florida.  The agreement provides ...
... REDWOOD CITY, Calif., Dec. 5, 2011 Codexis, Inc. (Nasdaq: ... has been named Vice President and Chief Marketing Officer.  ... for the company,s corporate marketing and communications.  He will ... Officer. Mr. Bolsen is a widely recognized ...
... 2011  Immune Design Corp. announced today that Wayne ... new Chief Development Officer.  Dr. Gombotz brings a ... key leadership position at Immune Design.  He will ... therapeutic vaccine product candidates. (Logo: ...
Cached Biology Technology:OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response 2OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response 3Codexis Names Wes Bolsen VP and Chief Marketing Officer 2Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer 2
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
(Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
(Date:11/10/2014)... Laundry detergent pods began appearing on U.S. store shelves ... growing numbers ever since. The small packets can be ... measure out a liquid or powder. The convenience, though, ... new study from researchers at Nationwide Children,s Hospital found ... received reports of 17,230 children younger than 6 years ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Study finds laundry detergent pods, serious poisoning risk for children 2
... delivers new insight about rapid toxin evolution in venomous snakes: ... race with opossums, a group of snake-eating American marsupials. Although ... this fact has not been factored into previous explanations for ... usually seen as a feeding, or trophic, adaptation. But new ...
... contrast agents that sneak into bacteria disguised as glucose ... sensitivity and specificity. These agents -- called maltodextrin-based imaging ... other inflammatory conditions. "These contrast agents fill the ... of bacteria in vivo and distinguish infections from other ...
... 18, 2011) Researchers from the John Theurer Cancer ... 14 cancer-related studies during the recently concluded American Society ... June 3 7, 2011 in Chicago. The studies ... treatment outcomes, and patient quality of life issues. ...
Cached Biology News:Rapid venom evolution in pit vipers may be defensive 2Rapid venom evolution in pit vipers may be defensive 3New contrast agents detect bacterial infections with high sensitivity and specificity 2New contrast agents detect bacterial infections with high sensitivity and specificity 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 2John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 3John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 4John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 5John Theurer Cancer Center researchers shared 14 leading edge studies at recent ASCO meeting 6